Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Tolero Pharmaceuticals

Request full access

A biopharmaceutical company, develops novel therapeutics to treat cancer and other life-threatening diseases

Salt Lake City, United StatesFounded 2011Biotech & Life Sciences

About Tolero Pharmaceuticals

Tolero Pharmaceuticals, Inc. operates as a clinical-stage biopharmaceutical firm focused on discovering and developing therapeutics for hematologic and oncologic diseases. Founded in 2011 by Dallin Anderson and David J. Bearss, the company is headquartered in Lehi, Utah. Dr. Bearss, a seasoned entrepreneur and drug developer with over two decades of experience in both academic and industry settings, has co-founded eight biotech companies and has discovered 16 compounds that have advanced to clinical development. His work concentrates on small-molecule drug development and utilizing genetic models for drug discovery.

The company's business model revolves around its internal research and development capabilities to build a pipeline of drug candidates. A key milestone for Tolero was the acquisition by the Japanese firm Sumitomo Dainippon Pharma in a deal announced in December 2016 and completed in January 2017. The acquisition, valued at up to $780 million, included a $200 million upfront payment with further milestone payments tied to development and commercial success. Following the acquisition, Tolero became a wholly-owned subsidiary of Sumitomo Dainippon Pharma America Holdings, Inc., and in July 2020, it was merged with Boston Biomedical to form Sumitomo Dainippon Pharma Oncology.

Tolero's lead product candidate is Alvocidib, a small molecule inhibitor of cyclin-dependent kinase 9 (CDK9). Alvocidib, which was licensed from Sanofi, targets the protein P-TEFb, which is involved in the transcription of cancer-related genes. By inhibiting CDK9, Alvocidib aims to suppress the production of MCL-1, a protein that helps cancer cells survive by preventing programmed cell death (apoptosis). This mechanism is being investigated for the treatment of hematologic malignancies such as Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS). Alvocidib has received Orphan Drug Designation in both the United States and Europe for the treatment of AML. The company is also developing TP-1287, an oral prodrug of Alvocidib, among other compounds in its pipeline targeting various oncologic pathways.

Source: Dealroom company data

Tolero Pharmaceuticals in the Salt Lake City ecosystem

Live from Dealroom

The Tolero Pharmaceuticals office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A1 investor entered at this stage

  • Fred Alger Management
Team profiled 4 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
🇺🇸 United States · Salt Lake City HQ
Book a demo for the full country breakdown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Tolero Pharmaceuticals on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Tolero Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.